public · ai application

Tempus AI

AI-driven precision medicine company using machine learning to analyze clinical and molecular data for cancer treatment decisions.

Bubble risk estimate

78/100

Confidence: medium

Value evidence

62/100

Checked: 2026-07-30

Coverage

Ticker: TEM

Market type: public

Confidence: medium

Scores are provisional research estimates, not price targets or recommendations.

Source-backed signals

Tempus AI

Risk upproduct release

Tempus AI announces $1.5B acquisition of cancer detection company Personalis

$1.5B acquisition

Tempus AI moved to acquire cancer genomics company Personalis for approximately $1.5 billion, expanding its genomic testing capabilities and clinical data moat.

Why it mattersThe acquisition accelerates Tempus's data advantage in precision medicine but increases integration risk and cash burn at a company already operating at a loss. Aggressive M&A at rich valuations is a hallmark of late-cycle AI enthusiasm.

Source: Eastmoney · Published 2026-07-15 · Checked 2026-07-30 · Confidence: medium

Tempus AI

Risk downrevenue

Tempus AI revenue grows 70% year-over-year, driven by AI-powered precision medicine demand

$1.36B TTM revenue, +70% YoY

Tempus AI reported approximately $1.36 billion in trailing twelve-month revenue, representing nearly 70% year-over-year growth, fueled by adoption of its AI-driven clinical and molecular data platform.

Why it mattersStrong top-line growth from a genuine AI application in healthcare provides real revenue evidence. However, the company remains unprofitable with negative free cash flow, and its $10.6 billion market cap implies a P/S ratio of approximately 7.8x, leaving room for valuation compression if growth decelerates.

Source: StockAnalysis · Published 2026-07-02 · Checked 2026-07-30 · Confidence: medium